OBJECTIVES: Clinical translation of tissue-engineered heart valves requires valve competency and lack of stenosis in the short and long term. Early studies of engineered valves showed promise, although lacked complete definition of valve function. Building on prior experiments, we sought to define the in vivo changes in structure and function of autologous engineered pulmonary valved conduits. METHODS: Mesenchymal stem cells were isolated from neonatal sheep bone marrow and seeded onto a bioresorbable scaffold. After 4 weeks of culture, valved conduits were implanted. Valve function, cusp, and conduit dimensions were evaluated at implantation (echocardiography), at the experimental midpoint (magnetic resonance imaging), and at explant, at 1 day, and 1, 6, 12, or 20 weeks postoperatively (direct measurement, echocardiography). Histologic evaluation was performed. RESULTS: Nineteen animals underwent autologous tissue-engineered valved conduit replacement. At implantation, valved conduit function was excellent; maximum transvalvular pressure gradient by Doppler echocardiography was 17 mm Hg; most valved conduits showed trivial pulmonary regurgitation. At 6 postoperative weeks, valve cusps appeared less mobile; pulmonary regurgitation was mild to moderate. At 12 weeks or more, valved conduit cusps were increasingly attenuated and regurgitant. Valved conduit diameter remained unchanged over 20 weeks. Dimensional measurements by magnetic resonance imaging correlated with direct measurement at explant. CONCLUSIONS: We demonstrate autologous engineered tissue valved conduits that function well at implantation, with subsequent monitoring of dimensions and function in real time by magnetic resonance imaging. In vivo valves undergo structural and functional remodeling without stenosis, but with worsening pulmonary regurgitation after 6 weeks. Insights into mechanisms of in vivo remodeling are valuable for future iterations of engineered heart valves. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
OBJECTIVES: Clinical translation of tissue-engineered heart valves requires valve competency and lack of stenosis in the short and long term. Early studies of engineered valves showed promise, although lacked complete definition of valve function. Building on prior experiments, we sought to define the in vivo changes in structure and function of autologous engineered pulmonary valved conduits. METHODS: Mesenchymal stem cells were isolated from neonatal sheep bone marrow and seeded onto a bioresorbable scaffold. After 4 weeks of culture, valved conduits were implanted. Valve function, cusp, and conduit dimensions were evaluated at implantation (echocardiography), at the experimental midpoint (magnetic resonance imaging), and at explant, at 1 day, and 1, 6, 12, or 20 weeks postoperatively (direct measurement, echocardiography). Histologic evaluation was performed. RESULTS: Nineteen animals underwent autologous tissue-engineered valved conduit replacement. At implantation, valved conduit function was excellent; maximum transvalvular pressure gradient by Doppler echocardiography was 17 mm Hg; most valved conduits showed trivial pulmonary regurgitation. At 6 postoperative weeks, valve cusps appeared less mobile; pulmonary regurgitation was mild to moderate. At 12 weeks or more, valved conduit cusps were increasingly attenuated and regurgitant. Valved conduit diameter remained unchanged over 20 weeks. Dimensional measurements by magnetic resonance imaging correlated with direct measurement at explant. CONCLUSIONS: We demonstrate autologous engineered tissue valved conduits that function well at implantation, with subsequent monitoring of dimensions and function in real time by magnetic resonance imaging. In vivo valves undergo structural and functional remodeling without stenosis, but with worsening pulmonary regurgitation after 6 weeks. Insights into mechanisms of in vivo remodeling are valuable for future iterations of engineered heart valves. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Authors: M K Sewell-Loftin; Young Wook Chun; Ali Khademhosseini; W David Merryman Journal: J Cardiovasc Transl Res Date: 2011-07-13 Impact factor: 4.132
Authors: Donal MacGrogan; Guillermo Luxán; Anita Driessen-Mol; Carlijn Bouten; Frank Baaijens; José Luis de la Pompa Journal: Cold Spring Harb Perspect Med Date: 2014-11-03 Impact factor: 6.915
Authors: Petra E Dijkman; Emanuela S Fioretta; Laura Frese; Francesco S Pasqualini; Simon P Hoerstrup Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: Nafiseh Masoumi; Aurélie Jean; Jeffrey T Zugates; Katherine L Johnson; George C Engelmayr Journal: J Biomed Mater Res A Date: 2012-07-24 Impact factor: 4.396
Authors: Nafiseh Masoumi; Benjamin L Larson; Nasim Annabi; Mahshid Kharaziha; Behnam Zamanian; Kayle S Shapero; Alexander T Cubberley; Gulden Camci-Unal; Keefe B Manning; John E Mayer; Ali Khademhosseini Journal: Adv Healthc Mater Date: 2014-01-22 Impact factor: 9.933
Authors: Aline L Y Nachlas; Siyi Li; Benjamin W Streeter; Kenneth J De Jesus Morales; Fatiesa Sulejmani; David Immanuel Madukauwa-David; Donald Bejleri; Wei Sun; Ajit P Yoganathan; Michael E Davis Journal: Biomaterials Date: 2020-02-12 Impact factor: 12.479
Authors: Bahar Fata; Christopher A Carruthers; Gregory Gibson; Simon C Watkins; Danielle Gottlieb; John E Mayer; Michael S Sacks Journal: J Biomech Eng Date: 2013-02 Impact factor: 2.097